Mesoblast Financial Results and Corporate Update Webcast
NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
Day: August 29, 2023
OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule
NEW YORK and LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused...
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
Maximizing global leadership of SYFOVRE in geographic atrophy (GA)Streamlining the EMPAVELI business and prioritizing development of systemic pegcetacoplan in IC-MPGN/C3GFocusing...
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women
Eagle plans to file a new drug application (“NDA”) for EA-114 in 2024 EA-114 is anticipated to meaningfully optimize the...
Castellum Announces the Award of a $3 million Contract to its Specialty Systems, Inc. Subsidiary
Castellum Announces the Award of a $3 million Contract to its Specialty Systems, Inc. Subsidiary Castellum, Inc. (NYSE-American: CTM) (“Castellum”)...
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of...
Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update
Achieved two landmark milestones with OCS-01, Oculis’ lead product candidate as first investigational eye drop for both front and back...
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
Bioventure Bioventure logo Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and BioventureAlvotech (NASDAQ:...
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
- Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and BioventureREYKJAVIK, Iceland and DUBAI,...
Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenous Tecentriq, including certain types of lung,...
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4BERKELEY,...
Red Light Holland Reports First Quarter 2024 Results
Cash balance of $17.5 million as at June 30, 2023Revenue of $1.2 million (vs 2022: $0.8 million, an increase of...
Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights
$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC")...
Dr. Parul Khator Becomes First Doctor In Georgia to Use the iTrack Advance Canaloplasty Device for Glaucoma
Minimally invasive device reduces intraocular pressure for adults with open angle glaucomaATLANTA--(BUSINESS WIRE)--Georgia Eye Partners is proud to share that...
Silo Wellness Announces LOI to Acquire NUGL/Kaya in a Transaction Valued at CAD $43,289,624.60; CSE to Halt Trading Until Shareholder Approval
Eugene, Oregon--(Newsfile Corp. - August 29, 2023) - Silo Wellness, Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) ("SILO") has confirmed...
Evotec SE Reports Results for the First Half-year 2023 and Provides Corporate Updates
NEW AND EXTENDED ALLIANCES UNDERLINE PIPELINE VALUE POTENTIALNEW GUIDANCE FOR FULL-YEAR 2023 CONFIRMEDHAMBURG, GERMANY / ACCESSWIRE / August 29, 2023...